RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Cholesterol drug boosts immunotherapy against tough head and neck cancers
Disease control Recruiting nowThis study tests whether adding a common cholesterol-lowering drug (lovastatin) to an immunotherapy (pembrolizumab) can help shrink tumors in people with head and neck cancer that has returned or spread. About 28 adults whose cancer has not responded to prior treatments will rece…
Matched conditions: RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 08:03 UTC
-
Could a Two-Drug punch before surgery beat head and neck cancer?
Disease control Recruiting nowThis study tests whether giving two immunotherapy drugs (cemiplimab and CDX-1140) before surgery works better than one drug alone for people with stage III-IV head and neck cancer. About 44 participants will receive either the combo or just cemiplimab before their tumor is remove…
Matched conditions: RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:51 UTC
-
Could a single immunotherapy drug replace harsh Chemo-Radiation after head and neck cancer surgery?
Disease control Recruiting nowThis study compares the immunotherapy drug pembrolizumab (Keytruda) against the usual combination of chemotherapy and radiation after surgery for head and neck cancer that has come back or is a new primary tumor. About 188 adults aged 18-79 with high-risk features (cancer at the …
Matched conditions: RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:27 UTC
-
New combo therapy aims to outsmart tough head and neck cancers
Disease control Recruiting nowThis study tests whether adding cetuximab to the immunotherapy drug pembrolizumab helps people with advanced head and neck cancer live longer than pembrolizumab alone. The trial enrolls about 158 adults whose cancer has returned or spread and no longer responds to platinum chemot…
Matched conditions: RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New vaccine combo aims to fight recurrent head and neck cancer
Disease control Recruiting nowThis early-phase trial tests a personalized vaccine made from a patient's own tumor cells, given alone or with an immunotherapy drug (pembrolizumab), for head and neck cancer that has returned or spread. The study aims to find the safest dose and check for side effects in 40 adul…
Matched conditions: RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Mayo clinic launches large study to find throat cancer markers
Knowledge-focused Recruiting nowThis study aims to find biological markers (biomarkers) that show up in the blood, tissue, or saliva when a person has HPV-related throat cancer, and disappear after successful treatment. Researchers will collect samples from 560 adults with or without the cancer to compare. The …
Matched conditions: RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 26, 2026 08:03 UTC